Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 11/20 | 0.84 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.82 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.82 |
| ▸ | LCK | P06239 | 4/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.64 |
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29624330 | 0.98 | MAPT (0.97) | MAPTGRM1EGFRNCOA1NCOA3 | |
| Hydrochloric Acid SCHEMBL7417527 | 0.98 | MAPT (0.97) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL2100465 | 0.92 | MAPT (0.84) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL6954080 | 0.91 | EGFR (1.00) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL15503743 | 0.90 | NCOA1 (1.00) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL11279693 | 0.89 | MAPT (0.80) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL28469600 | 0.89 | MAPT (0.80) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL4380336 | 0.86 | MAPT (0.76) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL22300487 | 0.86 | MAPT (0.74) | MAPTGRM1EGFRNCOA1NCOA3 | |
| SCHEMBL22300454 | 0.86 | MAPT (0.74) | MAPTGRM1EGFRNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2011156780-A2 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20100273864-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010074992-A2 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010062413-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2010011605-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | MAPT 2187/4885GRM1 1952/4885EGFR 1289/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | MAPT 2438/4885GRM1 4226/4885EGFR 4219/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | MAPT 2438/4885GRM1 4226/4885EGFR 4219/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, TLR3, STING1 | MAPT 3025/4885GRM1 2790/4885EGFR 1547/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | MAPT 2140/4885GRM1 3830/4885EGFR 3879/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
| US-20100273864-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | MAPT 2187/4885GRM1 1952/4885EGFR 1289/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | MAPT 2171/4885GRM1 2230/4885EGFR 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.